- Home
- BGH vs AMRN Comparison
BGH vs AMRN Comparison
Compare BGH & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$15.22
Company Overview
Basic Information| Metric | BGH | AMRN |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.7M | 339.8M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | BGH | AMRN |
|---|---|---|
| Price | $13.82 | $15.22 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 105.2K | 88.7K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $12.52 | $0.39 |
| 52 Week High | $16.90 | $20.90 |
Technical Indicators
Market Signals| Indicator | BGH | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 25.44 | 52.15 |
| Support Level | N/A | $14.65 |
| Resistance Level | $15.25 | $16.94 |
| Average True Range (ATR) | 0.14 | 0.74 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 16.05 | 51.00 |
Price Performance
Historical Comparison BGH
AMRN
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.